company background image
BDSX logo

Biodesix NasdaqGM:BDSX Stock Report

Last Price

US$1.69

Market Cap

US$245.3m

7D

-1.2%

1Y

-20.7%

Updated

04 Oct, 2024

Data

Company Financials +

Biodesix, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biodesix
Historical stock prices
Current Share PriceUS$1.69
52 Week HighUS$2.21
52 Week LowUS$1.15
Beta1.21
11 Month Change-7.65%
3 Month Change7.64%
1 Year Change-20.66%
33 Year Change-78.11%
5 Year Changen/a
Change since IPO-86.81%

Recent News & Updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Recent updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

A Second Look At Biodesix

Oct 18

Biodesix expects Q3 revenue above the consensus

Oct 11

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Aug 04

Biodesix: Bad Diagnosis

May 26

Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

Mar 15
Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates

Nov 25
Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates

Bearing In On Biodesix

Sep 13

Shareholder Returns

BDSXUS HealthcareUS Market
7D-1.2%-0.3%-0.7%
1Y-20.7%9.5%32.5%

Return vs Industry: BDSX underperformed the US Healthcare industry which returned 9.5% over the past year.

Return vs Market: BDSX underperformed the US Market which returned 32.5% over the past year.

Price Volatility

Is BDSX's price volatile compared to industry and market?
BDSX volatility
BDSX Average Weekly Movement6.6%
Healthcare Industry Average Movement7.1%
Market Average Movement6.4%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: BDSX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BDSX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005217Scott Huttonwww.biodesix.com

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to establish the patient’s prognosis and help guide treatment decisions.

Biodesix, Inc. Fundamentals Summary

How do Biodesix's earnings and revenue compare to its market cap?
BDSX fundamental statistics
Market capUS$245.35m
Earnings (TTM)-US$44.51m
Revenue (TTM)US$60.90m

4.0x

P/S Ratio

-5.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BDSX income statement (TTM)
RevenueUS$60.90m
Cost of RevenueUS$13.66m
Gross ProfitUS$47.25m
Other ExpensesUS$91.76m
Earnings-US$44.51m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.31
Gross Margin77.58%
Net Profit Margin-73.08%
Debt/Equity Ratio98.9%

How did BDSX perform over the long term?

See historical performance and comparison